tradingkey.logo

Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202

ReutersJun 5, 2025 11:22 AM

Regenxbio Inc RGNX.O:

  • REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

  • REGENXBIO INC - FAVORABLE SAFETY PROFILE CONTINUES WITH NO SERIOUS ADVERSE EVENTS OBSERVED IN RGX-202 TRIAL

  • REGENXBIO INC - PIVOTAL TRIAL EXPECTED TO SUPPORT BLA SUBMISSION USING ACCELERATED APPROVAL PATHWAY IN MID-2026

  • REGENXBIO INC -EXPECTS TO SHARE TOP-LINE DATA IN FIRST HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI